Characteristics of Long COVID-19 Syndrome

Active, not recruiting

• Conditions: Long COVID Syndrome
• Interventions: Other: No intervention

• Registration Number: NCT04793269
• Lead Sponsor: Christian Clarenbach

Brief Summary

Characterization of patients with long COVID syndrome including symptoms, medical history and persistent organ damage.

Detailed Description

Some people are very hesitant to recover from a COVID-19 infection and present persistent symptoms. The participants still suffer after the acute phase of the infection from shortness of breath, coughing, chest pain or fatigue. Therefore, a special interdisciplinary consultation was built. The consulatation is not only addressed to people who have been hospitalized due to COVID-19, but also to those with mild symptoms during infection. During the consultation hours, personal health data are collected that serves as the basis for this research project.

Study Timeline

• Study Start: 2021-02-23
• Study First Submitted: 2021-03-04
• Study First Submitted QC: 2021-03-09
• Study First Posted: 2021-03-11
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-25
• Last Update Posted: 2025-03-30
• Primary Completion: 2025-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Long COVID syndrome
• age >= 18 years
• Informed consent

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Long COVID	No intervention	Patients with long COVID syndrome

Primary Outcome Measures

Name	Time	Method
self-addressed Quality of life	once through study completion, an average of 6 months	Short form health 36 questionnaire with 8 domains, each rated from 0-100. The higher the score the better subjective quality of life.
Medical history	once through study completion, an average of 6 months	List of relevant morbidities assessed as present/not present by medical interview (e.g. respiratory, cardial, neurological, psychiatric diseases by interview and medical records)
Thoracic pain	once through study completion, an average of 6 months	assessed by medical interview (reported as yes or no)
Fibrosis	once through study completion, an average of 6 months	Assessed by chest CT, rated as present/not present
Myocardial damage	once through study completion, an average of 6 months	Assessed by myocardial damage, rated as present/not present
Dyspnea	once through study completion, an average of 6 months.	modified medical research council (scale from 0 to 4). The higher the score the worse the symptoms.

Trial Locations

Locations (1)

University Hospital Zurich; 🇨🇭 Zurich, Switzerland